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Background
Despite vaccination programmes being in place for de-
cades, the burden associated with influenza remains high,
particularly at the ends of the age spectrum. Hospitalisa-
tion rates are highest in young children [1], increasing
again in the elderly, where most of the deaths associated
with influenza are concentrated [2]. As with other
vaccines, two approaches exist – the first strategy targets
the groups most likely to develop complications following
infection, whereas the second targets the transmitters to
offer direct and indirect protection to the population
through reduced transmission in the community.
Approaches to influenza control
Historically, influenza control has focused on offering direct
protection to individuals most at risk, including those with
predisposing conditions, such as chronic respiratory diseases
or the immunocompromised, and the elderly. However,
given the remaining burden, many national programmes are
exploring the extension of coverage to other groups. In the
US, vaccination was extended to a universal programme
based on the high hospitalisation burden in young children
and, in the UK, a childhood vaccination programme has
been implemented following the licencing of a live-
attenuated influenza vaccine for younger age groups.
Influenza seasons are characterised by their variability,
with the three families of strains circulating every year at
different intensities. Similarly, the efficacy of influenza
vaccines also fluctuates year on year as a result of the
evolution of the circulating strains [3]. Assessing the
impact of any intervention has to account for this
uncertain background – a policy might appear very cost-
effective during a high intensity season whereas not so
in a quiet one or in a year when there is a poor fit
between the vaccine and the predominant strain.
In their recent article, de Boer et al. [4] assess the po-
tential dynamics resulting from repeatedly vaccinating
children against the flu season after season. For this, they
use an age-structured susceptible–infected–recovered
(SIR) model in which immunity is carried over from one
season to another but may wane over time (at a more
rapid rate for vaccine-derived immunity) [5]. They derive
scenarios of the likely impact of replacing some of the
immunity previously acquired through infections by that
acquired through vaccination. Their results suggest that,
in such a setting, vaccinating children is likely to be a
very cost-effective way of tackling influenza – at an esti-
mated €3944 per quality-adjusted life year (QALY)
gained, the policy is way below the Dutch national
threshold of €20,000 per QALY gained.
Other authors have similarly found that childhood vac-
cination may be cost-effective in high-income settings
[6, 7]. However, what distinguishes de Boer et al.’s [4]
analysis is suggesting the benefits of influenza vacci-
nation of children might come at the price of more year-
on-year variability in outbreak size. Indeed, they suggest
that in some years we would experience larger epidemics
than would have been expected without childhood
vaccination; this is vital as one of the motivations for
targeting children through an influenza programme is to
reduce the incidence during the winter period, thus
reducing winter pressures on health systems. In contrast
to a comparable study [7], De Boer et al. [4] also predict
that around 90% of the QALYs gained from the paedia-
tric vaccination programme would arise from preventing
deaths, with the remaining occurring through the pre-
vention of illness. As most fatalities occur in the elderly,
then most of the benefits of the programme fall to the
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older age groups, with the programme deemed not cost-
effective if considering the benefits to children alone.
These findings do not impact on the economic analysis,
as all relevant benefits and costs should be included;
however, they could have important equity and health
messaging implications if the main beneficiaries of the
programme are not those that are receiving the vaccine.
All models are simplifications of complex real-life
systems. The art in building a model is to eliminate
unnecessary complications, yet models can be criticised
for over-simplifying. In the case of transmission models
used to inform on influenza vaccination policies, there
has been a tendency to make crude assumptions about
natural and vaccine-induced immunity. For example,
evidence is mounting of an individual’s antibody re-
sponses being skewed towards the first strains encoun-
tered during their lifetime [8] and of a decrease in
antibody response following several infections. Trans-
lating and transposing measures of vaccine efficacy as
measured in the field into models is also difficult as pro-
tection can be against acquiring infection, transmission
or symptoms; these varying levels of protection will have
different effects on the dynamics and therefore, poten-
tially, on the cost-effectiveness of different policies. To
date, these more realistic assumptions about immunity
have not been adopted into economic analyses, including
that by de Boer et al. [4] – it remains to be seen how
important they may be.
Looking to the future
During the first years following the introduction of paediatric
influenza vaccination, the UK immediately piloted the new
programme in some regions while others had a more pro-
gressive introduction. This patchy and gradual introduction
lends itself to analysis as a natural experiment, yet the results
are difficult to interpret, particularly when added to the tem-
poral variability in influenza seasonal burden and vaccine ef-
fectiveness. At present, findings are not clear cut and appear
to vary between clinical endpoints. For instance, data sug-
gests that the programme might result in indirect protection
of unvaccinated age groups, with a reduction of physician
consultations for influenza-like illness in those aged over 17
years in the pilot areas; however, the same studies suggest
that there has been no apparent positive impact on excess
mortality [9, 10].
Conclusions
Making sense of this complex picture will take time.
This process may well be helped by fitting a model to
the data in an evidence synthesis approach or by com-
bining the information from the different pilot seasons
with a model to help quantify the impact of the
programme on different clinical endpoints. If de Boer
et al. [4] are right, then we might eventually see a worse
epidemic in areas that have had the highest coverage for
the longest time – thankfully, to date, nothing of the sort
has been observed and the risk remains theoretical.
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